Cumberland Pharmaceuticals Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Cumberland Pharmaceuticals Inc. (CPIX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $2.25 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2025-03-07
- Cumberland Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $2.25, a 11.76% decline from fiscal 2023.
- Cumberland Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $2.55, a 14.43% decline from fiscal 2022.
- Cumberland Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $2.98.
- Cumberland Pharmaceuticals Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|
| 2024-12-31 | $2.25 10-K · filed 2025-03-07 |
| 2023-12-31 | $2.55 10-K · filed 2025-03-07 |
| 2022-12-31 | $2.98 10-K · filed 2024-03-13 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-12 |
| 2019-12-31 | $13.00 10-K · filed 2021-03-12 |
| 2018-12-31 | $0.00 8-K · filed 2020-12-10 |
| 2017-12-31 | $0.00 10-K · filed 2019-03-12 |
| 2016-12-31 | $9.00 10-K · filed 2018-03-09 |
| 2015-12-31 | $7.41 10-K · filed 2017-03-13 |
| 2014-12-31 | $6.46 10-K · filed 2016-03-14 |
| 2013-12-31 | $6.25 10-K · filed 2015-03-09 |
| 2012-12-31 | $12.22 10-K · filed 2014-03-11 |
| 2011-12-31 | $10.24 10-K · filed 2013-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |